Program
BI 771716
A development code.
In Boehringer Ingelheim's pipeline, Antibody fragment
. Its studies are mostly in Geographic Atrophy, led by Boehringer Ingelheim.
Furthest: phase 2, since Dec 5, 20242 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 20 open or running | phase 2since Dec 5, 2024 | Aug 17, 2023 | none ahead |
- Named in Boehringer Ingelheim’s own pipeline as
BI 771716
, phase 2, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 17, 2023First study: phase 1 study in Geographic AtrophyFirst studyNCT06006585 · 20 enrolled · United States
- Dec 5, 2024Phase 2 study in Macular DegenerationNCT06722157 · 202 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Antibody fragment”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06722157Macular Degeneration · United States | 2 | Completed | Oct 26, 2026 | 202 |
| NCT06006585Geographic Atrophy · United States | 1 | Completed | May 24, 2024 | 20 |
How it is read
Names in the registry
- “BI 771716”, 2 entries
Codes read as this program: BI771716.
Conditions, from the studies’ own filings
- Geographic Atrophy, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.